Danaher to acquire Masimo in $9.9B all-cash deal

Danaher agreed to acquire Masimo for $180 per share in an all-cash transaction valuing the deal at roughly $9.9 billion enterprise value, implying ~18x estimated 2027 EBITDA (≈15x including expected synergies). Danaher projects Masimo will generate EBITDA >$530 million in 2027, deliver >$125 million in annual cost synergies and >$50 million in annual revenue synergies by year five, and expects the deal to add $0.15–$0.20 to adjusted EPS in the first full year and approximately $0.70 by year five; closing is expected in H2 2026 and will be funded with cash and debt. Market reaction was sharp: Danaher shares fell roughly 6% to about $200 while Masimo shares jumped about 35% to ~$175.

Analysis

Market structure: Danaher (DHR) gains complementary tech and cross‑sell optionality in acute-care monitoring while Masimo (MASI) shareholders capture immediate premium; competitors (GE Healthcare, Philips) face pressure on differentiated oximetry pricing and hospital procurement leverage. Transaction multiple (~18x 2027 EBITDA pre‑synergies, ~15x post‑synergies) signals consolidation in diagnostics and potential margin expansion if >$175M in annual synergies materialize, tightening supply of differentiated sensors and raising switching costs for customers.

Risk assessment: Key tail risks include regulatory/antitrust pushback, failure to realize >$175M synergies, and legacy IP/legal exposure by Masimo that could re‑ignite costly litigation; refinancing risk if credit spreads widen before close (deal closes H2 2026). Timeline: days—stock volatility and arb compression; weeks/months—financing terms and regulatory filings; quarters—realized EPS accretion (DHR: +$0.15–0.20 Y1, +$0.70 by Y5) may be delayed or diluted.

Trade implications: Immediate arb opportunity is tight—buy MASI up to $178 and hold to close H2 2026 provided regulatory path is clear, hedge market via small DHR short; consider buying DHR bond exposure if new issue spreads widen >50–100bp vs pre‑deal levels. Options: use 3–6 month DHR put spreads (protective, size 1–2% of book) to express near‑term downside while selling premium if implied vol spikes on financing announcements.

Contrarian angles: Consensus underestimates integration/IP/legal drag and overestimates synergy capture speed—18x pre‑synergy is aggressive versus medtech precedent (12–14x). Reaction may be overdone on both sides: MASI +35% compresses arb margin to ~1–3% annualized; DHR −6% likely overshoots unless refinancing costs rise >100bp. Monitor contract retention metrics and outstanding litigation timelines as early read‑throughs for execution risk.

Key Decisions for Investors

• Establish a merger‑arb long position in MASI (up to 2% of portfolio) at or below $178 per share, sizing so expected IRR ≥3% annualized to H2 2026 close; exit if regulator signals (SEC/DOJ/EC) surface within 60 days or if print of financing widens tender arbitrage below 1%.
• Initiate a modest 1–2% short/hedge of DHR equity via borrow or buy 3–6 month put spread (e.g., 1:1 5–8% OTM) with a hard stop if DHR trades below $185 or if new debt issuance spreads are ≤+50bp over Treasuries, to protect against integration/refinancing risk.
• Allocate 2–3% to DHR credit if new bonds price with a spread pickup ≥100bp versus pre‑deal curves for 5–7 year paper (buy on weakness); target total yield pickup of ≥150bp over peers and trim if spreads tighten by >30bp.
• If MASI implied volatility >35% and arb stays <3% outright, implement a hedged options arb: buy MASI shares and sell short‑dated covered calls at $180 strike (near tender) to generate carry, capping duration to 6–9 months and closing on any regulatory red flag within 30–60 days.